'; if(pArray.length >= 4) { i=2; } else if(pArray.length >= 3) { i=2; inline = ''; } else if(pArray.length >= 2) { i=1; inline = ''; } else if(pArray.length === 1) { i=0; inline = ''; } $('#librarydrawer_story_container script').each(function() { $(this).remove(); }); $(pArray[pArray.length - 1]).after(subscribeBox); $(pArray[i]).after(inline).after($('#librarydrawer_story_container')); $('#text-story').focus(function() { if ($(this).val() == 'EMAIL ADDRESS') { $(this).css({color: '#000000', backgroundColor: '#ffffff'}); $(this).val(''); } }); $('#text-story').blur(function() { var trim = $(this).val().replace(/[\s]/g, ''); if(trim === '') { $(this).val('EMAIL ADDRESS'); $(this).css({color: '#666666', backgroundColor: '#f8f8f8', border: '#666666 1px solid'}); } }); $('.content-subscribe .btn-submit').click(function() { var val = $('.content-subscribe .text').val(); if(val.search(/[a-z0-9!#$%&'*+\/=?^_`{|}~-]+(?:\.[a-z0-9!#$%&'*+\/=?^_`{|}~-]+)*@(?:[a-z0-9](?:[a-z0-9-]*[a-z0-9])?\.)+[a-z0-9](?:[a-z0-9-]*[a-z0-9])?/gi) === -1) { $('.content-subscribe .text').css('border', '#ff6600 1px solid'); $('.content-subscribe .text').focus(); return false; } return true; }); }); //-->

Anthem to cover female libido drug Addyi; Cigna and Aetna on the fence

Tools

Health insurers are on the fence about covering Sprout Pharmaceutical's new pill, Addyi, which treats low libido in women, reports the Indianapolis Business Journal. Anthem, for instance, said it will cover the pill in many cases, while Cigna and Aetna still are evaluating their policies. Express Scripts and CVS Health will continue to work on their policies as well. This may be troublesome for Sprout, since getting coverage from insurers is vital--the company only just gained approval for the pill from the Food and Drug Administration after having been previously rejected in 2010 and 2013. If insurers forgo covering the pill, women may have to dish out some $400 a month to see if the drug will work. Considering the pill's potential side effects, which involve fainting, insurers will focus on the safety and effectiveness of the treatment. Article